BioSpace News Archive

Mineralys Therapeutics, Inc. announced details of an expanded two-part Phase 2 clinical trial for lorundrostat as a potential therapy to treat patients with Stage 2 to 4 chronic kidney disease, which is expected to start enrolling patients in the second half of 2023.

Inhibikase Therapeutics, Inc. announced that it received written notice on July 17, 2023 from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC indicating that Inhibikase Therapeutics has regained full compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550, and that Inhibikase is in compliance with all applicable listing standards.

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, education and government, advanced technologies and applied materials industries, announced plans to relocate and significantly expand the company’s Bridgewater, N.J. Innovation Center.

Evogene Ltd today announced it has entered into securities purchase agreements with institutional investors (including SilverArc Capital Management, Altium Capital Management, LP and CVI Investments, Inc.) for the purchase and sale of 8,500,000 ordinary shares in a registered direct offering at a purchase price of $1.00 per ordinary share.

Janux Therapeutics, Inc. today announced interim Phase 1 clinical data for PSMA-TRACTr JANX007 in adult subjects with metastatic castration-resistant prostate cancer (mCRPC) and provided a pipeline update.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive topline results from the Phase 3 PAPILLON study evaluating RYBREVANT® in combination with chemotherapy in patients with newly diagnosed advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference ® 2023 (AAIC ® ).

Mirion announced that it has published its inaugural Corporate Social Responsibility Report, detailing the company’s focus and commitment to advancing along its corporate citizenship journey.

Novan, Inc. and its wholly owned subsidiary, EPI Health, LLC, announced that it has entered into a stalking horse asset purchase agreement with Ligand Pharmaceuticals, Inc. prior to filing voluntary petitions for relief under chapter 11 of title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

Elevar Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for its investigational drug rivoceranib.